Shares of G1 Therapeutics (NASDAQ: GTHX), a commercial-stage oncology company tanked in pre-market trading on Friday after it announced the pricing of an underwritten public offering of 7.7 million shares of its common stock at a public offering price of $6.50 per share. The company will receive total gross proceeds of $50.05 million.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
All the stock in the offering will be sold by G1 Therapeutics.
